While your journey may look different than others, you can still forge your own path with advocacy, columnist Marisa Zeppieri ...

Excessive production of type I interferon (IFN-I) — a molecule that mediates immune and inflammatory responses — in people with systemic lupus erythematosus (SLE) may be caused by small fragments of ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Despite what you’ve read, there is no established diet for lupus. There are certain foods that may improve life while living with lupus, and that are certain foods that can worsen your flares and how ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

PALIZADE, a Phase 2b clinical trial of Kezar Life Sciences’ investigational therapy zetomipzomib, is still enrolling systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe ...

Hemogenyx Pharmaceuticals and Rockefeller University recently agreed to collaborate on developing new treatments for lupus using the biotechnology company’s humanized mouse models. Hemogenyx, which is ...

Women with systemic lupus erythematosus (SLE) in the U.S. live on average 22 years less — and men an average of 12 fewer years — than members of the same sex among the public at large, according to ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on ...

A single infusion of mesenchymal stem cells (MSCs) — those that make cells of the cartilage, bone, and fat — decreased the number of auto-reactive immune cells in difficult-to-treat systemic lupus ...